NR3C2 and hydrops fetalis: With regard to HF treatments, European guidelines recommend the use of renin–angiotensin system inhibitors (preferably sacubitril/valsartan), beta-blockers, SGLT2is, and mineralocorticoid receptor antagonists as first-line therapies for patients with HFrEF (and with a lower strength of evidence for patients with HFmrEF).